Diabetic Eye Disease Pipeline Therapies Part 2: High-dose Aflibercept & Gene Therapy
| Overview / Abstract: |
This discussion with Program Chair Christina Y. Weng, MD, MBA, and Glenn Yiu, MD, PhD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial. Drs. Weng and Yiu also converse about the latest data on pipeline therapies for diabetic macular edema, including high-dose aflibercept & gene therapy. |
|
Expiration |
Dec 30, 2022 |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
0.5 |
|
Accreditation |
ACCME |
|
Keywords / Search Terms |
Evolve Medical Education LLC Free CE CME |
|